Yi Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Xue has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Yunqing Ren
Department of Dermatology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310058, China
3 shared publications - Jipeng Liu
Department of Dermatology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
2 shared publications - Qi Chen
Department of Dermatology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
2 shared publications - Bo-Cheng Yang
Department of Plastic Surgery, Zhongshan Hospital Affiliated to Xiamen University, School of Medicine, Xiamen University, Xiamen 361005, China
1 shared publication - Chengchao Chu
Xiamen University
1 shared publication Guang-Liang Cheng
Department of Pediatrics, Dongyang Women and Children’s Hospital, Dongyang, Zhejiang, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Nanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges
Lower respiratory infections (LRIs) remain a leading cause of global morbidity and mortality, particularly among vulnerable populations such as children and the elderly. Although conventional antimicrobial therapies remain central to clinical management, their efficacy is often limited by poor pulmonary bioavailability, systemic toxicity, inadequate penetration of mucus or biofilms, and the rapid emergence of drug-resistant pathogens. Nanodrug delivery systems (NDDS) provide a promising strategy to address these limitations by improving pulmonary deposition, protecting labile therapeutics, enabling controlled release, and supporting disease-site targeting. In this review, we systematically summarize recent advances in NDDS for LRIs, with emphasis on the design principles and functional characteristics of lipid-based, polymeric, inorganic, and hybrid nanocarriers. We further connect these platforms with disease-specific therapeutic challenges in bacterial pneumonia, tuberculosis, viral infections, and fungal pneumonia, highlighting how carrier composition, surface engineering, and release behavior can be adapted to mucus barriers, biofilms, intracellular pathogen niches, and inflammatory microenvironments. Importantly, we discuss emerging trends, including bioinspired nanocarriers, stimuli-responsive systems, and multifunctional theranostic platforms, while also evaluating key translational barriers such as biosafety, immunogenicity, reproducible manufacturing, and regulatory standardization.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Open AccessNanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges
Lower respiratory infections (LRIs) remain a leading cause of global morbidity and mortality, particularly among vulnerable populations such as children and the elderly. Although conventional antimicrobial therapies remain central to clinical management, their efficacy is often limited by poor pulmonary bioavailability, systemic toxicity, inadequate penetration of mucus or biofilms, and the rapid emergence of drug-resistant pathogens. Nanodrug delivery systems (NDDS) provide a promising strategy to address these limitations by improving pulmonary deposition, protecting labile therapeutics, enabling controlled release, and supporting disease-site targeting. In this review, we systematically summarize recent advances in NDDS for LRIs, with emphasis on the design principles and functional characteristics of lipid-based, polymeric, inorganic, and hybrid nanocarriers. We further connect these platforms with disease-specific therapeutic challenges in bacterial pneumonia, tuberculosis, viral infections, and fungal pneumonia, highlighting how carrier composition, surface engineering, and release behavior can be adapted to mucus barriers, biofilms, intracellular pathogen niches, and inflammatory microenvironments. Importantly, we discuss emerging trends, including bioinspired nanocarriers, stimuli-responsive systems, and multifunctional theranostic platforms, while also evaluating key translational barriers such as biosafety, immunogenicity, reproducible manufacturing, and regulatory standardization.
- Open Access
- 3 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2699
Urea Transporters in Cancer: Emerging Roles and Their Clinical Implications
Background/Objective: The SLC14A gene family in mammals encodes the urea transporters UT-A and UT-B (UTs), whose primary function is urea transport. In recent years, increasing research has shown that UTs are involved in tumor formation and progression. The purpose of this article is to review the current knowledge in the potential of urea transporters as tumor biomarkers and therapeutic targets. Methods: An extensive review of the literature was performed utilizing both PubMed and Web of Science databases focusing on articles published within the last ten years. Results: UTs are significantly downregulated in various tumor tissues. They are associated with the staging and prognosis of cancers such as bladder cancer (BC). They participate in the metabolic reprogramming of tumor cells via glycosylation, enhancing the energy supply and material synthesis of tumor cells. They participate in remodeling the tumor microenvironment, influencing the interactions between fibroblasts and tumor cells. Additionally, they interact with other signaling pathways to participate in tumorigenesis and development. Conclusions: The mechanisms by which UTs function in tumorigenesis and progression remain to be fully elucidated, but their potential as tumor biomarkers and therapeutic targets has gradually attracted attention.
- 3 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2699
Open AccessUrea Transporters in Cancer: Emerging Roles and Their Clinical Implications
Background/Objective: The SLC14A gene family in mammals encodes the urea transporters UT-A and UT-B (UTs), whose primary function is urea transport. In recent years, increasing research has shown that UTs are involved in tumor formation and progression. The purpose of this article is to review the current knowledge in the potential of urea transporters as tumor biomarkers and therapeutic targets. Methods: An extensive review of the literature was performed utilizing both PubMed and Web of Science databases focusing on articles published within the last ten years. Results: UTs are significantly downregulated in various tumor tissues. They are associated with the staging and prognosis of cancers such as bladder cancer (BC). They participate in the metabolic reprogramming of tumor cells via glycosylation, enhancing the energy supply and material synthesis of tumor cells. They participate in remodeling the tumor microenvironment, influencing the interactions between fibroblasts and tumor cells. Additionally, they interact with other signaling pathways to participate in tumorigenesis and development. Conclusions: The mechanisms by which UTs function in tumorigenesis and progression remain to be fully elucidated, but their potential as tumor biomarkers and therapeutic targets has gradually attracted attention.
- Open Access
- 18 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (9) , 1128
Applications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases
Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of disorders, including autoimmune, acute, and chronic inflammatory conditions, which are often characterized by immune dysregulation and excessive oxidative stress. Oxidative stress plays a pivotal role in the initiation and progression of these diseases by promoting tissue damage and sustaining inflammation. However, conventional antioxidant therapies are limited by poor bioavailability, inadequate targeting, and short-lived efficacy. In recent years, nano-antioxidants have emerged as a promising therapeutic approach due to their enhanced stability, targeted delivery capabilities, and multifunctional therapeutic effects. This review provides a comprehensive overview of recent advances in the application of nano-antioxidants in the treatment of IMIDs. Their therapeutic roles are categorized into three major groups: autoimmune diseases, acute inflammatory diseases, and chronic inflammatory diseases. In autoimmune disorders such as alopecia areata and multiple sclerosis, nano-antioxidants have demonstrated the ability to reduce oxidative damage, modulate immune responses, and alleviate clinical symptoms. In acute inflammatory conditions, including acute kidney injury and acute liver injury, these nanomaterials exert protective effects by scavenging ROS, mitigating tissue injury, and restoring organ function. In chronic inflammatory diseases such as inflammatory bowel disease and ulcerative colitis, nano-antioxidants contribute to maintaining mucosal integrity, suppressing chronic inflammation, and improving therapeutic outcomes through localized delivery and sustained release. In summary, nano-antioxidants represent a novel and promising therapeutic strategy for the management of IMIDs. Their unique physicochemical properties offer significant advantages over traditional treatments. Further research is needed to optimize their delivery platforms, evaluate long-term safety, and facilitate clinical translation.
- 18 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (9) , 1128
Open AccessApplications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases
Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of disorders, including autoimmune, acute, and chronic inflammatory conditions, which are often characterized by immune dysregulation and excessive oxidative stress. Oxidative stress plays a pivotal role in the initiation and progression of these diseases by promoting tissue damage and sustaining inflammation. However, conventional antioxidant therapies are limited by poor bioavailability, inadequate targeting, and short-lived efficacy. In recent years, nano-antioxidants have emerged as a promising therapeutic approach due to their enhanced stability, targeted delivery capabilities, and multifunctional therapeutic effects. This review provides a comprehensive overview of recent advances in the application of nano-antioxidants in the treatment of IMIDs. Their therapeutic roles are categorized into three major groups: autoimmune diseases, acute inflammatory diseases, and chronic inflammatory diseases. In autoimmune disorders such as alopecia areata and multiple sclerosis, nano-antioxidants have demonstrated the ability to reduce oxidative damage, modulate immune responses, and alleviate clinical symptoms. In acute inflammatory conditions, including acute kidney injury and acute liver injury, these nanomaterials exert protective effects by scavenging ROS, mitigating tissue injury, and restoring organ function. In chronic inflammatory diseases such as inflammatory bowel disease and ulcerative colitis, nano-antioxidants contribute to maintaining mucosal integrity, suppressing chronic inflammation, and improving therapeutic outcomes through localized delivery and sustained release. In summary, nano-antioxidants represent a novel and promising therapeutic strategy for the management of IMIDs. Their unique physicochemical properties offer significant advantages over traditional treatments. Further research is needed to optimize their delivery platforms, evaluate long-term safety, and facilitate clinical translation.
- Open Access
- 19 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 2015
Bullous Congenital Ichthyosiform Erythroderma with Tinea Capitis in Half-Siblings: Rare Phenomenon in Ichthyosis with Co-Existing Trichophyton rubrum Infection and Blocker Displacement Amplification for Mosaic Mutation Detection
Background/Objectives: Bullous congenital ichthyosiform erythroderma (BCIE) is an inherited keratinization disorder caused by pathogenic variants in specific genes. Here, we report a pair of half-siblings with BCIE and tinea capitis due to Trichophyton rubrum (T. rubrum) and then review the species of ichthyosis previously reported with T. rubrum infection. Methods: We performed dermatological examination, fungal culture, and genetic analysis using whole-exome sequencing (WES) and blocker displacement amplification (BDA)-based Sanger sequencing. Both patients received oral terbinafine once daily and topical bifonazole gel for tinea capitis. Results: The pair of half-siblings had exhibited generalized scaling and hyperkeratosis since birth. Both siblings subsequently developed scalp pustules and hair loss for several months. Genetic analysis identified a pathogenic variant in the keratin 10 (KRT10) gene, confirming BCIE diagnosis. Additionally, fungal culture revealed T. rubrum infection. The patients responded positively to oral terbinafine antifungal treatment. Conclusions: This case highlights the potential susceptibility of patients with BCIE to fungal infections, warranting clinical vigilance. Furthermore, it demonstrates the utility of the BDA-based mutation detection method for diagnosing BCIE, suggesting its promise for advancing personalized diagnosis and management in hereditary skin diseases.
- 19 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 2015
Open AccessBullous Congenital Ichthyosiform Erythroderma with Tinea Capitis in Half-Siblings: Rare Phenomenon in Ichthyosis with Co-Existing Trichophyton rubrum Infection and Blocker Displacement Amplification for Mosaic Mutation Detection
Background/Objectives: Bullous congenital ichthyosiform erythroderma (BCIE) is an inherited keratinization disorder caused by pathogenic variants in specific genes. Here, we report a pair of half-siblings with BCIE and tinea capitis due to Trichophyton rubrum (T. rubrum) and then review the species of ichthyosis previously reported with T. rubrum infection. Methods: We performed dermatological examination, fungal culture, and genetic analysis using whole-exome sequencing (WES) and blocker displacement amplification (BDA)-based Sanger sequencing. Both patients received oral terbinafine once daily and topical bifonazole gel for tinea capitis. Results: The pair of half-siblings had exhibited generalized scaling and hyperkeratosis since birth. Both siblings subsequently developed scalp pustules and hair loss for several months. Genetic analysis identified a pathogenic variant in the keratin 10 (KRT10) gene, confirming BCIE diagnosis. Additionally, fungal culture revealed T. rubrum infection. The patients responded positively to oral terbinafine antifungal treatment. Conclusions: This case highlights the potential susceptibility of patients with BCIE to fungal infections, warranting clinical vigilance. Furthermore, it demonstrates the utility of the BDA-based mutation detection method for diagnosing BCIE, suggesting its promise for advancing personalized diagnosis and management in hereditary skin diseases.
- Open Access
- 28 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 14 (1) , 27
Recent Trends in the Development and Application of Nano-Antioxidants for Skin-Related Disease
Skin is a vital barrier for the human body, protecting against external environmental influences and maintaining internal homeostasis. In addition, an imbalance of oxidative stress and antioxidant mechanisms can lead to skin-related diseases. Thus, for treating skin-related diseases, antioxidant therapy may be an important strategy to alleviate these symptoms. However, traditional drug therapies have limitations in treating these conditions, such as lack of lasting effect and insufficient skin permeability. Recently, nano-antioxidants, with their good permeability, sustained-release ability, multifunctionality, and other beneficial characteristics, have showed their advances in the exploration of skin-related diseases from research on safe therapies to clinical practice. Hereby, we review the latest research and advancements in nano-antioxidants for skin-related diseases. We categorize skin-related diseases into four main groups: skin inflammatory diseases, skin damage caused by ultraviolet rays, skin wound healing, and other skin-related conditions. Additionally, we summarize the prospects and potential future directions for nano-antioxidant drugs in treating skin-related diseases.
- 28 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 14 (1) , 27
Open AccessRecent Trends in the Development and Application of Nano-Antioxidants for Skin-Related Disease
Skin is a vital barrier for the human body, protecting against external environmental influences and maintaining internal homeostasis. In addition, an imbalance of oxidative stress and antioxidant mechanisms can lead to skin-related diseases. Thus, for treating skin-related diseases, antioxidant therapy may be an important strategy to alleviate these symptoms. However, traditional drug therapies have limitations in treating these conditions, such as lack of lasting effect and insufficient skin permeability. Recently, nano-antioxidants, with their good permeability, sustained-release ability, multifunctionality, and other beneficial characteristics, have showed their advances in the exploration of skin-related diseases from research on safe therapies to clinical practice. Hereby, we review the latest research and advancements in nano-antioxidants for skin-related diseases. We categorize skin-related diseases into four main groups: skin inflammatory diseases, skin damage caused by ultraviolet rays, skin wound healing, and other skin-related conditions. Additionally, we summarize the prospects and potential future directions for nano-antioxidant drugs in treating skin-related diseases.